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doi:10.1016/j.jmii.2011.11.015Background/Purpose: A growing number of b-lactamases have been reported in Pseudomonas
aeruginosa isolates. The aims of this study were to survey the types of extended-spectrum
b-lactamases (ESBLs) by polymerase chain reaction (PCR), to evaluate the reliability of pheno-
typic tests for ESBLs, and to identify the clonal distribution by pulsed-field gel electrophoresis
(PFGE) among P. aeruginosa isolates resistant to expanded-spectrum cephalosporins (ceftazi-
dime, aztreonam, or cefepime).
Methods: The antimicrobial susceptibility of 57 P. aeruginosa isolates from blood specimens
were examined according to the recommendations of the Clinical Laboratory Standards Insti-
tute. ESBL phenotypes were determined by using cloxacillin-containing double disc synergy
test (DDST). The existence of 11 b-lactamase genes was detected by PCR.
Results: Of the 57 P. aeruginosa isolates, 35 (61.4%) isolates were PCR-positive for b-lactamase
genes. Twelve of 35 isolates were PCR-positive for combination of ampC and ESBL genes,
including TEM, GES, SHV, VEB and OXA-I genes. The sensitivity and specificity of cloxacillin-
containing DDST (using the criteria of ceftazidime zone diameter increased S5 mm) were
84.1% and 54.5%, respectively. Nine clusters were classified among 35 PCR-positive isolates
by PFGE. Isolates of clusters B and C were distributed in different wards of this hospital during
a period of 3e4 years.
Conclusion: ESBL genes are not uncommon in P. aeruginosa isolates. Cloxacillin-containing
DDST can enhance the sensitivity and has a potential role for phenotypic detection ofnfectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, No. 160,
0705 Taiwan, ROC.
v.tw (Z.-Y. Shi).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Extended-spectrum b-lactamases of P. aeruginosa 201ESBL-producing P. aeruginosa, and PCR is also helpful for the identification of specific
b-lactamase genes. These P. aeruginosa isolates were classified into several diverse clones
which could continue to spread in the hospital over a long period of time.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Pseudomonas aeruginosa is a pathogen commonly impli-
cated in serious nosocomial infections such as pneumonia,
urinary tract infection, and sepsis. P. aeruginosa is also
notably resistant to many classes of antimicrobial agents,
including b-lactams, aminoglycosides and fluoroquinolones.
The development of b-lactam resistance in this opportu-
nistic pathogen can be caused by several mechanisms:
(1) genetic mutations that lead to stable overexpression
of AmpC, a chromosome-mediated cephalosporinase; (2)
acquisition of transferable genes that code for a variety of
b-lactamases; (3) overproduction of efflux systems; and
(4) reduced permeability.1 A growing number of Ambler
class A extended-spectrum b-lactamases (ESBLs), class B
carbapenemases [metallo-b-lactamases (MBLs)], and class
D extended-spectrum oxacillinases (OXAs) have been
reported in clinical strains of P. aeruginosa.2e4
ESBLs are a rapidly growing group of b-lactamases
that hydrolyze broad-spectrum cephalosporins as well as
aztreonam. ESBL expression also confers penicillin and
narrow-spectrum cephalosporin resistance. ESBLs are
inhibited by b-lactamase inhibitors such as clavulanic acid.
Over 200 different ESBLs have been identified in Gram-
negative bacilli. Thirty-two ESBLs have been detected in
P. aeruginosa, which can be categorized into two molecular
classes A and D, and further divided into eight subgroups:
TEM-, SHV-, CTX-M-, PER-, VEB-, GES-, BEL-, and OXA-type
b-lactamases.5 TEM- and SHV-type enzymes are the most
common ESBLs found in enterobacterial species, whereas
OXA- and PSE-types are most frequently encountered in
P. aeruginosa.2
AmpC b-lactamases are class C cephalosporinases and
have been identified in Enterobacteriaceae and P. aerugi-
nosa. Class Cmolecules contribute to the intrinsic resistance
of Enterobacteriaceae and P. aeruginosa to penicillins and
cephalosporins, as well as a combination of b-lactams and
b-lactamase inhibitors.5 In P. aeruginosa, resistance to
ceftazidime mostly results from overexpression of its natu-
rally occurring AmpC-type cephalosporinase.6
Resistance to various b-lactamases of class A, B and C
among Enterobacteriaceae has been reported in Taiwan.7e13
Only one study has ever reported ESBLs (focusing on OXA-
types) of P. aeruginosa in Taiwan.14 Three ESBLs belonging
to the OXA-types were identified in 1294 P. aeruginosa
isolates, including OXA-14 (0.2%), OXA-17 (2.8%) and OXA-10
(0.6%). Surveillance of the various types of ESBLs found in
P. aeruginosa has not been reported in Taiwan. The double
disc syngery test (DDST) has been recommended by the
Clinical Laboratory Standards Institute (CLSI) as a phenotypic
test of ESBL in Escherichia coli and Klebsiella pneumoniae.15
However, due to sensitivity of the phenotypic test, the
application of DDST to P. aeruginosa has only been reportedin a small subset of studies.16 Phenotypic detection of ESBLs
can be obscured by the chromosomal AmpC cephalospor-
inase in P. aeruginosa because AmpC is not inhibited by
b-lactamase inhibitors (e.g., clavulanic acid).17 With the
addition of cloxacillin, ESBL detection in P. aeruginosa by
DDST can be enhanced through the inhibition of AmpC
enzyme activity.
The aims of this study were to survey the antimicrobial
susceptibility and types of ESBLs in P. aeruginosa by poly-
merase chain reaction (PCR) and to evaluate the reliability
of phenotypic tests for ESBLs among P. aeruginosa, and to
identify the clonal distribution of P. aeruginosa by pulse-
field gel electrophoresis (PFGE).
Materials and methods
Bacterial strains
A total of 765 P. aeruginosa isolates from blood samples were
collected from 2005 to 2009 at the Microbiology Laboratory
of Taichung Veterans General Hospital; a 1000-bed medical
center in central Taiwan. Fifty-seven P. aeruginosa isolates
resistant to expanded-spectrum cephalosporins (ceftazi-
dime, aztreonam or cefepime) as determined by disc diffu-
sion method were selected from the total sample for this
study.
Antimicrobial susceptibility tests and detection of
ESBLs by phenotypic tests
Susceptibility test
The minimum inhibitory concentrations (MICs) of nine anti-
microbial agents: piperacillin/tazobactam (Wyeth, Phila-
delphia, USA), piperacillin (Wyeth), aztreonam (Bristole
Myers Squibb, New York, NY, USA), amikacin (BristoleMyers
Squibb), cefepime (BristoleMyers Squibb), imipenem (MSD,
Rahway, NJ, USA), ceftazidime (GlaxoSmithKline, London,
UK), ceftazidime/clavulanate (GSK) and ciprofloxacin
(Bayer, Leverkusen, Germany) were assessed using the
broth microdilution method according to CLSI recommen-
dations.15 The antibiotics were serially diluted twofold in
5 mL cation-adjusted MuellereHinton broth (CAMHB). The
final range of antibiotic concentrations was 0.125e256 mg/
mL. The bacterial suspension was prepared from actively
growing bacteria in 4 mL CAMHB, and diluted to a bacterial
cell density of 1  106 colony forming units (CFU)/mL. Five
microliters of bacterial suspension was then added to wells
containing 100 mL serially diluted antimicrobial agents to
yield a final inoculum of approximately 5  104 CFU/mL. The
MICs were read after overnight incubation (18e24 hours)
at 35C. The susceptibility was interpreted according to
the breakpoints suggested by the CLSI.18 All MICs were
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ATCC 27853 were used as the quality control strains.
DDST and cloxacillin-based DDST
To detect possible ESBL production, conventional DDST was
performed with discs containing ceftazidime (30 mg) and
ceftazidime (30 mg)/clavulanic acid (10 mg).18 ESBL
production was inferred if the zones produced by the disks
with ceftazidime (30 mg)/clavulanic acid (10 mg) were
S5 mm larger than that of ceftazidime (30 mg). Pheno-
typic detection of ESBLs can be obscured by the chromo-
somal AmpC cephalosporinase in P. aeruginosa, hence
cloxacillin-containing DDST was performed. Cloxacillin
(250 ug/mL; Sigma, St Louis, MO, USA) was added in Muel-
lereHinton agar to inhibit cephalosporinase activity.16
After overnight culture, test isolates were suspended to
0.5 turbidity using McFarland standards as a reference, and
used to inoculate a MuellereHinton agar plate containing
250 mg/mL cloxacillin. After drying, discs containing cefta-
zidime, ceftazidime/clavulanic acid, aztreonam and cefe-
pime were placed 2 cm from a disc containing amoxicillin/
clavulanic acid.19 After 18 hours incubation, cephalospor-
inase inhibition was considered positive using two criteria:
the ceftazidime zone diameter increased 5 mm and
>10 mm.16 The sensitivity and specificity were compared
between these two criteria.
Molecular techniques
PCR for detection of Ambler class A, C and D b-lactamases
P. aeruginosa DNA was prepared by guanidium thiocyanate
extraction as previously described.20 Two bacterial pellets
(3 mm in diameter) were taken from nutrient agar and
dispersed in 100 mL 10 mM TriseHCl (pH 8.0) and 1 mM
EDTA. The cells were lysed with 500 mL GES reagent [5 M
guanidiumthiocyanate (Sigma), 0.1 M EDTA, and 0.5% (w/v)
sarcosyl (Sigma)]. After addition of 250 mL 7.5 M ammonium
acetate, the suspension was kept on ice for 10 minutes. For
deproteination, 500 mL chloroformeisoamyl alcohol (24:1)
was added and the mixture was centrifuged at 13,000 g for
10 minutes. The DNA was precipitated from the upper
phase with 100% ethanol at e20C for 1 hour. The extracted
DNA (0.1 mg) was used as a template for amplification.
Eleven primer pairs for screening the Ambler class A ESBLs
(blaVEB, blaPER, blaGES, blaTEM, blaSHV, blaCTX, blaBEL), Class D
blactamases (blaOXA-group I, blaOXA-group II, blaOXA-group III),
and class C b-lactamases (blaAmpC) genes were used in the
PCR2,19,21,22 (Table 1). Amplification was performed in 50 mL
of final reaction mixture containing 2 U Taq polymerase
(Super Taq; HT Biotechnology Ltd., Cambridge, UK), 10 mM
TriseHCl, 200 mM deoxynucleotide triphosphates, and
0.5 mM of each primer. Amplification was performed in
a PTC-200 Thermal cycler (MJ Research, Watertown, MA,
USA) with temperatures as follows: 95C for 5 minutes to
denature the template; 30 cycles of 95C for 1 minute,
50C or 62C for 1 minute, and 72C for 1 minute; finally,
72C for 10 minutes. A negative control was run for each
amplification. The amplified products were analyzed by
electrophoresis on a 1.6% agarose gel containing ethidium
bromide (1 mg/mL) at 50 V/cm for 80 minutes, and were
detected by UV transillumination.PFGE
PFGE was performed with a contour-clamped homogeneous
electric field DRII apparatus from Bio-Rad Laboratories
(Richmond, CA, USA) as described previously.23 The chro-
mosomal DNA was digested overnight with SpeI (GIBCO-BRL,
Life Technologies, Gaithersburg, MD, USA). DNA was
electrophoresed in 1.2% SeaKem GTG agarose (FMC Bio-
products, Rockland, ME, USA) at 6 V/cm for 24 hours; the
pulse time was increased from 5 seconds to 35 seconds. The
PFGE patterns were also analyzed with the computer soft-
ware Gelcompar for Windows version 3.1b (Applied Math,
Kortrijk, Belgium). The PFGE patterns were compared by
the UPGMA (unweighted pair group method with arithmetic
averages) clustering method by using the Dice coefficient,
based on the instructions of the Gelcompar manufacturer. A
tolerance in the band position of 1.2% was applied during
the comparison of PFGE fingerprinting patterns. Isolates
were consider as a cluster if the relatedness was >80%.
Results
Suspectibility
The activity of antimicrobial agents against 57 isolates of P.
aeruginosa is summarized in Table 2. The MIC for 50% and
90% of P. aeruginosa isolates (MIC50/MIC90) of amikacin,
aztreonam, cefepime, ceftazidime, ceftazidime/clavulanic
acid, imipenem, piperacillin, piperacillin/tazobactam and
ciprofloxacin was 2/8, 32/256, 4/32, 32/256, 0.25/32,
1/16, S256/S256, S256/S256 and 0.25/2 mg/mL,
respectively. The susceptibility rates of ceftazidime and
piperacillin determined by disc diffusion differed from
those performed by broth microdilution. Amikacin had the
highest susceptibility rate, whereas aztreonam had the
lowest.
PCR of Ambler A, C and D b-lactamases
Table 3 shows the PCR results of Ambler A, C and D
b-lactamases in 57 P. aeruginosa isolates. Of all the 57 P.
aeruginosa isolates, 22 (38.6%) were PCR-negative for
Ambler A, C or D b-lactamases. Thirty-five (61.4%) isolates
were PCR-positive for b-lactamase genes, including 22
(38.6%) isolates for ampC alone, one (1.6%) for TEM alone,
and 12 (21.1%) for multiple b-lactamase genes. Of the 13
isolates with class A ESBL genes, TEM-type enzyme was
most common (13 isolates). Only two isolates carried the
OXA group I gene. CTX-M, PER, BEL, OXA group II and OXA
group III genes were not detected in this study. The MIC
ranges and susceptible rates of ceftazidime, ceftazidime/
clavulanic acid, piperacillin and piperacillin/tazobactam in
various combinations of b-lactamase genes are shown in
Table 3. The MIC of ceftazidime and piperacillin was not
decreased in the presence of b-lactamase inhibitors (clav-
ulanic acid and tazobactam).
PFGE of P. aeruginosa isolates
The PFGE patterns of 35 PCR-positive P. aeruginosa isolates
are shown in Fig. 1. A dendrogram was constructed to show
Table 1 Primers used in this study
Class of -lactamases Primer name Sequence (50 to 30) Product size (bp) Target Reference
Class A VEB-1A cgacttccatttcccgatgc 643 blaVEB
19
VEB-1B ggactctgcaacaaatacgc
PER-A atgaatgtcattataaaagc 920 blaPER
19
PER-B aatttgggcttagggcagaa
GES-1A atgcgcttcattcacgcac 864 blaGES
19
GES-1B taatcagtgaggcacctatctc
TEM-A gagtattcaacatttccgtgtc 851 blaTEM
19
TEM-B taatcagtgaggcacctatctc
SHV-A aagatccactatcgccagcag 231 blaSHV
19
SHV-B attcagttccgtttcccagcgg
CTX-MA cgctttgcgatgtgcag 550 CTXM-1,-2,-9 group 20
CTX-MB accgcgatatcgttggt
BEL-1FW cgacaatgccgcagctaacc 449 blaBEL-1
21
BEL-1RV cagaagcaattaataacgccc
Class D OXA-10F tctttcgagtacggcattagc 760 OXA group I 20
OXA-10B ccaatgatgccctcactttcc
OXA-2F gccaaaggcacgatagttgt 700 OXA group II 20
OXA-2B gcgtccgagttgactgccgg
OXA-1A agccgttaaaattaagccc 908 OXA group III 20
OXA-1B cttgattgaagggttgggcg
Class C AmpC-PA1 atgcagccaacgacaaagg 1243 blaamPC
22
AmpC-PA2 cgccctcgcgagcgcgcttc
Extended-spectrum b-lactamases of P. aeruginosa 203the degree of relatedness among the strains of nine clusters
(AeI). There were nine clusters among the 35 PCR-positive
isolates. The largest cluster, C, consisted of six isolates that
were isolated during 2007e2009. The second cluster, B,
included four isolates that were recovered from 2005 to
2009. Three closely related clusters (D, G and H) were
isolated within a shorter duration of time. Cluster D
included two isolates that were found in June 2008 and May
2009. Cluster G included two isolates that were isolated in
September and October 2005. Cluster H included two
isolates that were recovered in May and June 2006.Table 2 Activity of nine antimicrobial agents against 57








Amikacin 2 8 93.0 91.2
aztreonam 32 256 17.5 17.5
Cefepime 4 32 66.7 59.6
Ceftazidime 32 256 24.6 56.1
Ceftazidime/clavulanic
acid
32 256 24.6 ND
Imipenem 1 16 75.4 70.2
Piperacillin 256 256 35.1 ND
piperacillin/tazobactam 256 256 36.8 52.6
Ciprofloxacin 0.25 32 68.4 71.9
MIC Z minimum inhibitory concentration; MIC50 Z MIC for 50%
of isolates; MIC90 Z MIC for 90% of isolates; ND Z not done.DDST and cloxacillin-based DDST screening
Table 4 shows the sensitivity and specificity of DDST and
cloxacillin-containing DDST screening for detection of
ESBL. The sensitivity and specificity in the DDST for
ESBL-producing P. aeruginosa was 7.7% and 100%, respec-
tively. According to the experimental criteria, the
cloxacillin-based DDST was considered positive if the cef-
tazidime zone diameter increased >10 mm, and the
sensitivity and specificity were 38.5% and 84.1%, respec-
tively. A cloxacillin-based DDST was negative according to
the experimental criteria if the ceftazidime zone diameter
increased S5 mm, and the sensitivity increased to 76.9%;
however, the specificity decreased to 54.5%.
Discussion
According to the criteria of CLSI, all isolates with MICs
S2 mg/mL for ceftazidime, ceftriaxone, cefotaxime or
aztreonam are potential ESBL producers in Enter-
obacteriaceae.15 The CLSI recommends that a confirma-
tory clavulanic acid inhibition test be performed on
positive screening test clinical isolates.15 Detection of
ESBLs by DDST with clavulanic acid and extended-
spectrum cephalosporins is sensitive and specific for the
detection of ESBLs in the Enterobacteriaceae.24,25 The
Enterobacteriaceae with elevated MIC, positive screen
test and positive confirmatory test may cause ESBL genes;
while a negative ESBL confirmatory test, indicates the
presence of ampC or a combination of ampC and ESBL in
the Enterobacteriaceae.7,26
Similarly, the DDST may not be sensitive enough for the
detection of ESBLs in P. aeruginosa.16 These false-negative
Table 3 PCR results and susceptibility of Ambler A, C, and D b-lactamase genes for 57 Pseudomonas aeruginosa isolates
b-lactamases No. (%)
of isolates





PCR-negative 22 (38.6) 4e256/40.9 4e256/40.9 8 to 256/31.8 4 to 256/36.3
PCR-positive:
AmpC alone 22 (38.6) 8e256/22.7 8e256/22.7 8 to 256/50.0 8 to 256/50.0
AmpCþTEM 8 (14.0) 32e256/0.0 16e256/0.0 32 to 256/25.0 32 to 256/25.0
AmpCþTEMþSHV 1 (1.6) 64/0.0 128/0.0 256/0.0 256/0.0
AmpCþTEMþGES 1 (1.6) 32/0.0 64/0.0 256/0.0 256/0.0
AmpCþTEMþOXA-I 1 (1.6) 32/0.0 64/0.0 256/0.0 256/0.0
AmpCþTEMþOXA-IþVEB 1 (1.6) 256/0.0 256/0.0 256/0.0 256/0.0
VEB
TEM alone 1 (1.6) 64/0.0 64/0.0 256/0.0 256/0.0
MIC Z minimum inhibitory concentration; PCR Z polymerase chain reaction.
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encoded ampC genes that may be overexpressed; (2) simul-
taneous presence of MBLs with carbapenem-hydrolyzing
activities; (3) relative resistance to inhibition by clav-
ulanate, as exemplified by GES-2; and (4) combined mecha-
nisms of resistance, such as impermeability and efflux.2
There is no standardized method for the detection of
ESBLs in P. aeruginosa. Current ESBL detection methods,
based on the inhibitory effect of clavulanic acid on the
activities of ESBLs against extended-spectrum cephalospo-
rins, are inadequate for the detection of ESBLs in P. aeru-
ginosa.27,28 The inhibition of AmpC enzyme activity with
the addition of cloxacillin could enhance the abilities of
DDST to detect ESBLs in P. aeruginosa.16 De Champs et al16
have revealed that the cloxacillin-containing DDST had
a low sensitivity rate involving the detection of ESBL-
producing P. aeruginosa when utilizing experimental
criteria with a ceftazidime zone diameter increase of
>10 mm. Jiang et al29 also have compared various
screening methods for detecting ESBLs in 34 clinical isolates
of P. aeruginosa whose b-lactamases were well character-
ized.29 Among the total of 34 isolates, only 10 (29.4%)
strains were positive for a conventional DDST. The sensi-
tivity was increased to 82.4% in DDST that contained
250 mg/mL cloxacillin, when using the experimental criteria
of a ceftazidime zone diameter increase ofS5 mm.29 In our
study, the sensitivity for detecting ESBLs in P. aeruginosa
was only 7.7%, and the specificity was 100% by conventional
DDST; the sensitivity was increased to 38.5% and the
specificity was 84.1% by cloxacillin-containing DDST
(experimental criteria, ceftazidime zone diameter increase
>10 mm). Furthermore, the cloxacillin-based DDST was
considered positive by adjusting the experimental criteria
(the ceftazidime zone diameter increase of S5 mm), the
sensitivity was increased to 76.9%; however, the specificity
was decreased to 54.5%. The sensitivity of cloxacillin-
containing DDST is higher than that of conventional DDST,
especially using the experimental criteria of a ceftazidime
zone diameter increase of S5 mm. The cloxacillin-
containing DDST was helpful for the phenotypic detection
of ESBLs in P. aeruginosa.
The MICs to ceftazidime and piperacillin were not
decreased in the presence of b-lactamase inhibitors(clavulanic acid and tazobactam) in PCR-positive strains.
In this study, 35 (61.4%) of 57 P. aeruginosa isolates were
PCR-positive for b-lactamase genes. Among these 35 PCR-
positive isolates, 34 (97.1%) were positive for the ampC
gene. AmpC b-lactamases are cephalosporinases, which
contribute to intrinsic resistance to most b-lactams and
b-lactamase inhibitors. Of the 34 AmpC-producing P. aeru-
ginosa isolates, 29 (85.3%) isolates were not susceptible to
ceftazidime. In P. aeruginosa, the overexpression of the
naturally occurring AmpC is associated with decreased
susceptibility or resistance to expanded-spectrum cepha-
losporins such as ceftazidime.16,22,30 However, ampC genes
were not detected in 23 isolates by PCR. Further studies
using different primer pairs of ampC genes are necessary to
identify the AmpC subtypes.
Of the 13 isolates with class A ESBL genes, TEM-type
enzymes were most prevalent (12 isolates, 92.3%). Only two
isolates carried the OXA group I gene, and three isolates
carried SHV, GES and VEB, respectively. CTX-M, PER, BEL,
OXA group II and OXA group III genes were not detected in
this study. These findings are different from those outside
Taiwan. The b-lactamases PER-1 was the first ESBL identi-
fied and fully characterized in P. aeruginosa, which
occurred in 1993.31,32 ESBLs in P. aeruginosa are now
reported worldwide. ESBLs of TEM and SHV types are rarely
observed in P. aeruginosa,2 however, ESBLs of other types
have spread in this species within specific geographical
locations: PER-1b-lactamases are most widespread in
Turkey,33 VEB-1 in Southeast Asia,34 GES-like b-lactamases
have been identified in French, Greek, and South African
isolates,35e37 and BEL in Belgium.38
Besides ESBLs, the MBLs are also being reported in
growing numbers in P. aeruginosa isolates. Surveillance of
b-lactamases production by P. aeruginosa in Taiwan has
focused on MBLs.39e41 Yan et al have indicated that both
IMP- and VIM-type MBLs have emerged in Pseudomonas spp.
In Taiwan, the VIM-2-related enzymes are the most preva-
lent types.39,40 Huang et al also have described the higher
prevalence of the MBL genes among P. aeruginosa isolates
in Taiwan (36.0% in 2000 and 17.0% in 2002) compared with
neighboring countries.41 However, MBL genes were beyond
the scope of this study; instead, we only focused on ESBL
and ampC genes. Further surveillance of the b-lactamases
Figure 1. Dendrogram of 35 PCR-positive Pseudomonas
aeruginosa isolates. The numbers on the right side indicated
the isolate numbers. Nine clusters (AeI) were classified.
Table 4 Sensitivity and specificity in DDST and cloxacillin-








5 mm >10 mm 5 mm >10 mm
DDST 7.7% d 100% d
Cloxacillin-DDST 76.9% 38.5% 54.5% 84.1%
DDST Z ouble disc synergy test.
Extended-spectrum b-lactamases of P. aeruginosa 205carried by P. aeruginosa could identify the change and
spread of the b-lactamase genes.
Three isolates with GES, OXA and VEB belonged to three
different clusters (C, D and F, respectively). This finding
could be explained by horizontal transfer of resistance genecarried by mobile genetic elements. Isolates of clusters B
and C were distributed in different wards of this hospital
during a period of 3e4 years. They were isolated from
sporadic cases of infections rather than outbreak. However,
these sporadic isolates actually originated from common
ancestors.
In conclusion, ESBL genes are not uncommon in P.
aeruginosa isolates. The fact that the P. aeruginosa isolates
carried a combination of ampC and ESBL genes could result
in the failure of detection of an ESBL phenotype by
conventional DDST. Cloxacillin-containing DDST can enhance
the sensitivity and has a potential role for phenotypic
detection of ESBL-producing P. aeruginosa. PCR is also
helpful for the identification of specific b-lactamase genes.
These P. aeruginosa isolates were classified into several
diverse clones which could continue to spread in the
hospital over a long period of time.Acknowledgments
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